Pharmacokinetics and Safety of Three Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women.
Jyoti S MathadRada SavicPaula BrittoPriya JayachandranLubbe WiesnerGrace MontepiedraJennifer NormanNan ZhangEllen TownleyNahida ChakhtouraSarah BradfordSandesh PatilStephanie PopsonTsungai ChipatoVanessa RouzierDeborah LangatAmphan ChalermchockcharoentkitPortia KamthunziAmita GuptaKelly E Dooleynull nullPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021)
3HP does not require dose adjustment in pregnancy. Rifapentine clearance is higher among women with HIV, but all women achieved exposures of rifapentine and isoniazid associated with successful tuberculosis prevention. The data support proceeding with larger safety-focused studies of 3HP in pregnancy.
Keyphrases
- mycobacterium tuberculosis
- pregnancy outcomes
- pregnant women
- hiv aids
- pulmonary tuberculosis
- preterm birth
- antiretroviral therapy
- hiv positive
- human immunodeficiency virus
- hiv infected
- hepatitis c virus
- polycystic ovary syndrome
- hiv testing
- air pollution
- electronic health record
- adverse drug
- machine learning
- metabolic syndrome
- emergency department
- type diabetes
- men who have sex with men
- skeletal muscle
- south africa
- deep learning
- drug induced